Comprehensive medication guide to Journavx including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
With the Journavx savings program, commercially insured patients may pay as little as $30 per fill; without coverage, expect the full cash price.
Estimated Cash Pricing
Journavx costs approximately $477–$657 for 30 tablets (50 mg) without insurance.
Medfinder Findability Score
55/100
Summarize with AI
On this page
Journavx (Suzetrigine) is a groundbreaking non-opioid pain medication approved by the FDA in January 2025 for the treatment of moderate to severe acute pain in adults. Developed by Vertex Pharmaceuticals, it is the first NaV1.8 sodium channel blocker approved for clinical use. Unlike opioids, Journavx does not carry a risk of addiction or dependence, making it a significant advancement in pain management. It does not have a boxed warning and is not a controlled substance.
Journavx works by selectively blocking NaV1.8 sodium channels, which are found predominantly in peripheral pain-sensing neurons (nociceptors) in the dorsal root ganglia. It has over 3,100 times greater affinity for NaV1.8 than other voltage-gated sodium channels, allowing it to block pain signals in peripheral nerves before they reach the central nervous system. Because it does not act on the brain's reward system, Journavx has — a key advantage over traditional opioid painkillers.
![Why Is Journavx So Hard to Find? [Explained for 2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2Fda1aa456041ec445ab72faf7fc9f59fbba381e02-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
![How to Find a Doctor Who Can Prescribe Journavx Near You [2026 Guide]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F354b2b46d6c968a8f134937e627eca4e897940dd-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
50 mg oral tablets
Blue, film-coated, oblong tablets debossed with "VX50." The starting dose is 100 mg (two 50 mg tablets) taken on an empty stomach, followed by 50 mg every 12 hours. Maximum supply is 61 tablets per 30-day period.
Journavx receives a findability score of 55 out of 100, meaning it can be intermittently difficult to locate. As a brand-new, first-in-class non-opioid pain medication approved in January 2025 by Vertex Pharmaceuticals, not all pharmacies stock it yet. There is no generic version available, and patent protection extends through approximately 2040. Availability varies by region and pharmacy — larger chain pharmacies and specialty pharmacies are more likely to carry it. If your local pharmacy doesn't have it, ask them to order it or use Medfinder to locate a pharmacy with Journavx in stock near you.
Since Journavx is not a controlled substance, any licensed prescriber can write a prescription for it. Common prescribers include:
No, Journavx is not a controlled substance. It has no DEA scheduling, requires no PDMP (Prescription Drug Monitoring Program) checks, and carries no risk of addiction or dependence. This is one of its most significant advantages over opioid pain medications — prescribers can write for it without the regulatory burden associated with controlled substances, and patients do not face the stigma or monitoring requirements that come with opioid prescriptions.
Most side effects of Journavx are mild to moderate. Common side effects include:
Serious but rare side effects may include severe allergic reactions and significant creatine kinase elevation. Contact your doctor immediately if you experience signs of an allergic reaction or unexplained muscle pain. Journavx carries no boxed warning.
Know what you need? Skip the search.
Ibuprofen (Advil, Motrin)
An over-the-counter NSAID for mild to moderate pain
Naproxen (Aleve)
An over-the-counter NSAID for mild to moderate pain
Acetaminophen (Tylenol)
A non-NSAID analgesic for mild to moderate pain
Celecoxib (Celebrex)
A COX-2 selective NSAID for pain and inflammation
Ketorolac (Toradol)
A potent prescription NSAID for short-term moderate to severe pain
Prefer Journavx? We can find it.
Strong CYP3A inhibitors (CONTRAINDICATED)
moderateDo not take Journavx with ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat, or other strong CYP3A inhibitors
Moderate CYP3A inhibitors (dose adjustment needed)
moderateErythromycin, fluconazole, diltiazem, and verapamil may require dose modifications
Hormonal contraceptives
moderateJournavx is a CYP3A inducer and may reduce the effectiveness of hormonal birth control (except levonorgestrel and norethindrone). Use additional non-hormonal contraception during treatment and for 28 days after stopping
Grapefruit and grapefruit juice
moderateAvoid during treatment as it may increase Journavx levels
Journavx (Suzetrigine) represents a major breakthrough as the first non-opioid medication in a new class for treating moderate to severe acute pain. With no risk of addiction, no controlled substance restrictions, and a novel mechanism of action, it offers a genuinely different approach to pain management. The main challenges are its high cash price ($477–$657 for 30 tablets) and inconsistent insurance coverage — many plans do not yet include it on their formularies or require prior authorization. The JOURNAVX+you savings program can bring costs down to as little as $30 per fill for eligible commercially insured patients. If you're having trouble finding Journavx at your local pharmacy, use Medfinder to locate a pharmacy with it in stock near you.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini